<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="178322">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00773695</url>
  </required_header>
  <id_info>
    <org_study_id>ML21744</org_study_id>
    <nct_id>NCT00773695</nct_id>
  </id_info>
  <brief_title>A Study of Avastin (Bevacizumab) in Combination With Neoadjuvant Treatment Regimens in Patients With Primary HER2 Negative Breast Cancer</brief_title>
  <official_title>A Multicenter, Randomized, ph II Clinical Trial to Evaluate the Effect of Avastin in Combination With Neoadj Treatment Regimens on the Molecular and Metabolic Characteristics and Changes in the Primary Tumors With Ref to the Obtained Responses in Patients With Large Primary HER2 Neg Breast Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian Radium Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This 2 arm study will evaluate the effect of Avastin, in combination with chemotherapy or
      endocrine therapy, as preoperative treatment in patients with HER2 negative breast cancer.
      Patients will be randomized to receive either chemotherapy (FEC100 for 4 x 3weekly cycles or
      endocrine therapy (an aromatase inhibitor daily for 24 weeks)with or without Avastin
      (15mg/kg iv every 3 weeks).The anticipated time on study treatment is 3-12 months, and the
      target sample size is 100-500 individuals.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRI determinants of pathological complete response</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular changes in protein kinase, mRNA/miRNA and protein expression; SNP profiles predicting treatment response; treatment-induced changes in tumor cells.</measure>
    <time_frame>Thoughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>iv every 3 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard chemotherapy or endocrine therapy</intervention_name>
    <description>As prescribed</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab [Avastin]</intervention_name>
    <description>15mg/kg iv every 3 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients, &gt;=18 years of age;

          -  HER2-negative breast cancer, &gt;=2.5cm in size;

          -  ECOG/WHOperformance status &lt;=2;

          -  normal baseline cardiac function (LVEF).

        Exclusion Criteria:

          -  stage IV (metastatic) disease;

          -  previous treatment for localized breast cancer &lt; 24 months from diagnosis of present
             breast cancer;

          -  other previous or current cancer except for basal cell cancer or in situ cervical
             cancer;

          -  current or recent use of aspirin (&gt;325mg/day);

          -  clinically significant cardiovascular disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <zip>0379</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trondheim</city>
        <zip>7000</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 1, 2016</lastchanged_date>
  <firstreceived_date>October 15, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
